A dual transcription factor activation method enables rapid generation of vascular organoids, accelerating modeling and ...

Myelodysplastic syndromes (MDS) are a group of disorders that typically arise in adulthood, especially after the age of 70, ...

Stanford researchers design blood vessels for 3D printed hearts - developing a faster, more precise way to model and print vascular systems.

There are more than 100,000 people on organ transplant lists in the U.S., some of whom will wait years to receive one – and some may not survive the wait. Even with a good match, there is a chance ...

The purpose of this study was to test the structure of the Fugl-Meyer Assessment for Upper Extremity (FMA-UE ... Rasch analysis using a rating scale model was performed, and item difficulty was ...

The publication, titled "Budget impact model of acellular tissue engineered vessel for the repair of extremity arterial trauma when autologous vein is not feasible,” reported that Symvess was ...

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

RPVI (UCSF Fresno), who will join company management to discuss the commercial plans and early market-launch success of Symvess (acellular tissue engineered vessel-tyod) for extremity arterial injury.

Symvess, or the ATEV™ (acellular tissue engineered vessel ... limb amputation and infection. To communicate the health economic value of Symvess, Humacyte has developed a Budget Impact Model ...

today announced an update of plans for the commercial launch of Symvess (acellular tissue engineered vessel-tyod) for extremity arterial injury. Humacyte is responding to requests for quotations ...